title: Magnetic resonance metabolic imaging of glioma.
abstract: 2-Hydroxyglutarate (2-HG) is a potential oncometabolite involved in gliomagenesis that has been identified as an aberrant product of isocitrate dehydrogenase (IDH)-mutated glial tumors. Recent genomics studies have shown that heterozygous mutation of IDH genes 1 and 2, present in up to 86% of grade II gliomas, is associated with a favorable outcome. Two reports in this issue describe both ex vivo and in vivo methods that could noninvasively detect the presence of 2-HG in glioma patients. This approach could have valuable implications for diagnosis, prognosis, and stratification of brain tumors, as well as for monitoring of treatment in glioma patients.
authors.affiliation: Department of Neurosurgery, Hôpital de la Timone, APHM, 13005 Marseille, France. philippe.metellus@mail.ap-hm.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Metellus
authors.forename: Dominique
authors.initials: D
authors.lastname: Figarella-Branger
mesh_terms: D001932:Brain Neoplasms / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D005910:Glioma / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009154:Mutation; D011379:Prognosis
chemical_list: D007521:Isocitrate Dehydrogenase